Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - National Advisory Unit on Late Effects after Cancer Treatment

13 publications found

Aas K, Berge V, Myklebust TA, Fossa SD (2021)
Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens
Eur. Urol. Open Sci., 26, 55-63

ArdeshirRouhaniFard S, Dinh PC, Monahan PO, Fossa SD, Huddart R, Fung C, Song Y, Feldman DR, Hamilton RJ, Vaughn DJ, Martin NE, Kollmannsberger C, Einhorn L, Kroenke K, Travis LB (2021)
Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study
Cancer Epidemiol Biomarkers Prev, 30 (6), 1129-1138
DOI 10.1158/1055-9965.EPI-20-1762, PubMed 33849970

Bjerring AW, Fosså SD, Haugnes HS, Nome R, Stokke TM, Haugaa KH, Kiserud CE, Edvardsen T, Sarvari SI (2021)
The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up
Eur Heart J Cardiovasc Imaging, 22 (4), 443-450
DOI 10.1093/ehjci/jeaa289, PubMed 33152065

Blindheim AJ, Fosså SD, Babigumira R, Andreassen BK (2021)
The use of reTURB in T1 bladder cancer: a Norwegian population-based study
Scand J Urol
DOI 10.1080/21681805.2021.1917652, PubMed 33998957

Eikeland SA, Smeland KB, Mols F, Fagerli UM, Bersvendsen HS, Kiserud CE, Fosså A (2021)
Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life
Acta Oncol, 1-10 (in press)
DOI 10.1080/0284186X.2021.1917776, PubMed 33905285

Hernæs KH, Smeland KB, Fagerli UM, Kiserud CE (2021)
Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation
BMC Cancer, 21 (1), 143
DOI 10.1186/s12885-021-07836-2, PubMed 33557789

Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G (2021)
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
Breast Cancer Res, 23 (1), 17
DOI 10.1186/s13058-021-01393-z, PubMed 33526044

Kurch L, Mauz-Körholz C, Fosså A, Georgi TW, Kluge R, Bartelt JM, Kunze C, Wohlgemuth WA, Pelz T, Vordermark D, Plößl S, Hasenclever D, Sabri O, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Løndalen AM, Steiner D, Krombach G, Attarbaschi A, Hoffmann M, Ceppi F et al. (2021)
Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial
Pediatr Blood Cancer, 68 (4), e28903
DOI 10.1002/pbc.28903, PubMed 33538093

Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK et al. (2021)
Burkitt Lymphoma International Prognostic Index
J Clin Oncol, 39 (10), 1129-1138
DOI 10.1200/JCO.20.03288, PubMed 33502927

Park J, Choi JY, Choi J, Chung S, Song N, Park SK, Han W, Noh DY, Ahn SH, Lee JW, Kim MK, Jee SH, Wen W, Bolla MK, Wang Q, Dennis J, Michailidou K, Shah M, Conroy DM, Harrington PA, Mayes R, Czene K, Hall P, Teras LR, Patel AV et al. (2021)
Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
Cancers (Basel), 13 (10)
DOI 10.3390/cancers13102370, PubMed 34069208

Skalleberg J, Myhrum M, Småstuen MC, Osnes TA, Fosså SD, Bunne M (2021)
Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?
Acta Oncol, 60 (4), 426-433
DOI 10.1080/0284186X.2021.1887514, PubMed 33617403

van den Berg MH, van Dijk M, Byrne J, Berger C, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, Haupt R, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, van der Kooi ALF, Kremer LCM, Kruseova J, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Spix C, Twisk JWR, Ronckers CM, Kaatsch P, van Dulmen-den Broeder E et al. (2021)
Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE)
Hum Reprod, 36 (6), 1561-1573
DOI 10.1093/humrep/deab035, PubMed 33744927

van der Kooi ALF, van Dijk M, Broer L, van den Berg MH, Laven JSE, van Leeuwen FE, Lambalk CB, Overbeek A, Loonen JJ, van der Pal HJ, Tissing WJ, Versluys B, Bresters D, Beerendonk CCM, Ronckers CR, van der Heiden-van der Loo M, Kaspers GL, de Vries ACH, Robison LL, Hudson MM, Chemaitilly W, Byrne J, Berger C, Clemens E, Dirksen U et al. (2021)
Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function
Hum Reprod, 36 (4), 1120-1133
DOI 10.1093/humrep/deaa342, PubMed 33582778

 
Page visits: 596253